You are here: Home: Audio Program Guide: LCU Nurses 1 | 2008 Audio: LCU Nurses 1 | 2008

 
   
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
Steagall, MD Ann Fish-Steagall, RN, BSN, OCN
Clinical Coordinator
Multidisciplinary Thoracic
Oncology Program
University of North Carolina at
Chapel Hill
Chapel Hill, North Carolina		  
  Click here to download entire interview  
Track 1 Case discussion: A 59-year-old woman who never smoked and presented with bilateral lymphangitic
spread of adenocarcinoma of the lung
Track 2 Clinical trial participation as an important treatment option
Track 3 Clinical trial evaluating erlotinib with chemotherapy versus erlotinib alone for never smokers with advanced adenocarcinoma
Track 4 Side effects of erlotinib
Track 5 Nursing management of erlotinib-induced skin rash
Track 6 Erlotinib-related hair and skin changes
Track 7 Gastrointestinal toxicities secondary to erlotinib
Track 8 Clinical response to erlotinib in a patient with an epidermal growth factor receptor (EGFR) mutation
Track 9 Symptomatic disease progression in the meninges
Track 10 Pulse erlotinib for the treatment of carcinomatous meningitis
Track 11 Timing of placement of venous access devices and bevacizumab
Track 12 Nurse’s philosophy on coping in an oncology practice
Track 13 Financial and toxicity-related issues for patients on long-term therapy for metastatic disease
Track 14 Oncology nurse’s perspective on toxicities associated with biologic therapies
Track 15 Nanoparticle albumin-bound (nab) paclitaxel in the treatment of lung cancer

 
Socinski, MD Mark A Socinski, MD
Professor of Medicine
Multidisciplinary Thoracic
Oncology Program
Lineberger Comprehensive
Cancer Center
University of North Carolina
Chapel Hill, North Carolina
  
  Click here to download entire interview  
Track 1 Rapid onset of symptoms in a patient with advanced lung cancer
Track 2 Conveying hope when counseling patients with advanced disease
Track 3 Diagnostic implications of a TTF1-positive immunophenotype
Track 4 Relationship between squamous cell lung cancer and bevacizumab-associated pulmonary hemorrhage
Track 5 ECOG-E4599: Eligibility criteria for the Phase III study of paclitaxel/carboplatin with or without bevacizumab in advanced NSCLC
Track 6 Efficacy data from ECOG-E4599
Track 7 Mechanisms of action of bevacizumab
Track 8 Toxicity data from ECOG-E4599
Track 9 Cavitation, histology and treatment-associated hemorrhage
Track 10 Relationship between EGFR mutations and lung cancer in the never smoker
Track 11 Clinical trials of EGFR tyrosine kinase inhibitors
Track 12 Identifying enriched populations with EGFR-activating mutations
Track 13 Rationale for administering erlotinib and/or bevacizumab to a never smoker
Track 14 Impact of erlotinib on quality of life
Track 15 Bevacizumab for disease progression after first-line erlotinib
Track 16 Treatment of leptomeningeal metastases
Track 17 Efficacy and toxicity of vandetanib (ZD6474)
Track 18 Potential benefits of nab paclitaxel
Track 19 Clinical response to pulse erlotinib for carcinomatous meningitis
Track 20 Helping patients with metastatic disease to attain their goals
 
Thomas J Lynch, MD
Massachusetts General Hospital
Chief, Hematology Oncology
Director, Center for
Thoracic Cancers
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
  
  Click here to download entire interview  
Track 1 Discovery of the EGFR mutation associated with lung cancer in never smokers
Track 2 Mechanisms to inhibit signaling in EGFR-mutated lung cancer
Track 3 Hypertrichosis secondary to erlotinib
Track 4 Mechanisms of resistance to tyrosine kinase inhibitor therapy in patients with EGFR mutations and the rationale for multidrug therapies
Track 5 Novel techniques for isolating circulating tumor cells
Track 6 Molecular pathology and identifying changes in oncogenes
Track 7 Use of tyrosine kinase inhibitors in the treatment of brain metastasis and carcinomatous meningitis
Track 8 Bevacizumab and tumor vasculature normalization and improved delivery of chemotherapy
Track 9 Cavitation as a risk factor for bevacizumab-related pulmonary hemorrhage
Track 10 Development of the multikinase inhibitor vandetanib in NSCLC
 
  Ms P

  
  Click here to download entire interview  
Track 1 Patient’s experience when diagnosed with Stage IV lung cancer
Track 2 Side effects of erlotinib from the patient’s point of view
Track 3 Patient’s perspective on living with advanced lung cancer